Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality
Treatment modalities for desmoid tumors have been changed because of the high recurrence rate, even after wide resection, and some cases experience spontaneous self-regression during clinical course. The treatment modality in our institutions before 2003 was surgical resection with wide surgical mar...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2012-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/4/1/88/ |
| _version_ | 1797764844749848576 |
|---|---|
| author | Naoki Ishiguro Eisuke Arai Yoshihiro Nishida Satoshi Tsukushi Hiroshi Urakawa Yoji Shido |
| author_facet | Naoki Ishiguro Eisuke Arai Yoshihiro Nishida Satoshi Tsukushi Hiroshi Urakawa Yoji Shido |
| author_sort | Naoki Ishiguro |
| collection | DOAJ |
| description | Treatment modalities for desmoid tumors have been changed because of the high recurrence rate, even after wide resection, and some cases experience spontaneous self-regression during clinical course. The treatment modality in our institutions before 2003 was surgical resection with wide surgical margin, however, meloxicam, which is a NSAID and a selective COX-2 inhibitor has been applied consecutively since 2003. We reviewed the previously reported outcomes of surgical and conservative treatment in our institutions. Among 30 patients receiving surgical treatment, 16 (53%) recurred. Younger age ( p < 0.05) was a significant poor factor. According to RECIST for meloxicam treatment, CR was in one, PR in 10, SD in eight, PD in one evaluated at 2011. Older age ( p < 0.01) was significantly associated with good outcome for meloxicam treatment. Results of the previous study indicated that surgical treatment alone could not control desmoid tumors, even with negative surgical margin. Considering the functional impairment resulting from surgery with negative surgical margin, a conservative and effective treatment modality with fewer complications is desired. Conservative treatment with meloxicam is a promising novel modality for patients with extra-abdominal desmoid tumors. |
| first_indexed | 2024-03-12T20:02:32Z |
| format | Article |
| id | doaj.art-26feec4ac21942498b98bc09f1228ccd |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T20:02:32Z |
| publishDate | 2012-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-26feec4ac21942498b98bc09f1228ccd2023-08-02T02:19:04ZengMDPI AGCancers2072-66942012-02-0141889910.3390/cancers4010088Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University ModalityNaoki IshiguroEisuke AraiYoshihiro NishidaSatoshi TsukushiHiroshi UrakawaYoji ShidoTreatment modalities for desmoid tumors have been changed because of the high recurrence rate, even after wide resection, and some cases experience spontaneous self-regression during clinical course. The treatment modality in our institutions before 2003 was surgical resection with wide surgical margin, however, meloxicam, which is a NSAID and a selective COX-2 inhibitor has been applied consecutively since 2003. We reviewed the previously reported outcomes of surgical and conservative treatment in our institutions. Among 30 patients receiving surgical treatment, 16 (53%) recurred. Younger age ( p < 0.05) was a significant poor factor. According to RECIST for meloxicam treatment, CR was in one, PR in 10, SD in eight, PD in one evaluated at 2011. Older age ( p < 0.01) was significantly associated with good outcome for meloxicam treatment. Results of the previous study indicated that surgical treatment alone could not control desmoid tumors, even with negative surgical margin. Considering the functional impairment resulting from surgery with negative surgical margin, a conservative and effective treatment modality with fewer complications is desired. Conservative treatment with meloxicam is a promising novel modality for patients with extra-abdominal desmoid tumors.http://www.mdpi.com/2072-6694/4/1/88/extra-abdominal desmoidsmeloxicamCOX-2conservative therapysurgery |
| spellingShingle | Naoki Ishiguro Eisuke Arai Yoshihiro Nishida Satoshi Tsukushi Hiroshi Urakawa Yoji Shido Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality Cancers extra-abdominal desmoids meloxicam COX-2 conservative therapy surgery |
| title | Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality |
| title_full | Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality |
| title_fullStr | Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality |
| title_full_unstemmed | Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality |
| title_short | Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality |
| title_sort | transition of treatment for patients with extra abdominal desmoid tumors nagoya university modality |
| topic | extra-abdominal desmoids meloxicam COX-2 conservative therapy surgery |
| url | http://www.mdpi.com/2072-6694/4/1/88/ |
| work_keys_str_mv | AT naokiishiguro transitionoftreatmentforpatientswithextraabdominaldesmoidtumorsnagoyauniversitymodality AT eisukearai transitionoftreatmentforpatientswithextraabdominaldesmoidtumorsnagoyauniversitymodality AT yoshihironishida transitionoftreatmentforpatientswithextraabdominaldesmoidtumorsnagoyauniversitymodality AT satoshitsukushi transitionoftreatmentforpatientswithextraabdominaldesmoidtumorsnagoyauniversitymodality AT hiroshiurakawa transitionoftreatmentforpatientswithextraabdominaldesmoidtumorsnagoyauniversitymodality AT yojishido transitionoftreatmentforpatientswithextraabdominaldesmoidtumorsnagoyauniversitymodality |